346 related articles for article (PubMed ID: 28645247)
1. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas.
Lee K; Lee KB; Jung HY; Yi NJ; Lee KW; Suh KS; Jang JJ
BMC Cancer; 2017 Jun; 17(1):441. PubMed ID: 28645247
[TBL] [Abstract][Full Text] [Related]
2. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of Yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma.
Kim GJ; Kim H; Park YN
PLoS One; 2013; 8(9):e75449. PubMed ID: 24086533
[TBL] [Abstract][Full Text] [Related]
4. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type.
Chen J; He J; Deng M; Wu HY; Shi J; Mao L; Sun Q; Tang M; Fan XS; Qiu YD; Huang Q
Hum Pathol; 2017 Jun; 64():118-127. PubMed ID: 28431889
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma.
Ryu HS; Lee K; Shin E; Kim SH; Jing J; Jung HY; Lee H; Jang JJ
Tumori; 2012; 98(4):478-84. PubMed ID: 23052165
[TBL] [Abstract][Full Text] [Related]
8. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma.
Yuan RH; Jeng YM; Hu RH; Lai PL; Lee PH; Cheng CC; Hsu HC
J Gastrointest Surg; 2011 Feb; 15(2):321-9. PubMed ID: 21061181
[TBL] [Abstract][Full Text] [Related]
9. Molecular alterations of the NF2 gene in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Zhang N; Zhao Z; Long J; Li H; Zhang B; Chen G; Li X; Lv T; Zhang W; Ou X; Xu A; Huang J
Oncol Rep; 2017 Dec; 38(6):3650-3658. PubMed ID: 29130106
[TBL] [Abstract][Full Text] [Related]
10. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
[TBL] [Abstract][Full Text] [Related]
11. BSEP and MDR3: Useful Immunohistochemical Markers to Discriminate Hepatocellular Carcinomas From Intrahepatic Cholangiocarcinomas and Hepatoid Carcinomas.
Fujikura K; Yamasaki T; Otani K; Kanzawa M; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
Am J Surg Pathol; 2016 May; 40(5):689-96. PubMed ID: 26735860
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Value of Cytokeratin and Sal-Like Protein 4 Expression in Hepatocellular Carcinoma and Intra-Hepatic Cholangiocarcinoma in Taiwan.
Lai YS; Cheng CC; Lee MT; Chao WT; Lai YC; Hsu YH; Liu YH
Int J Med Sci; 2018; 15(14):1746-1756. PubMed ID: 30588199
[No Abstract] [Full Text] [Related]
14. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.
Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S
Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic Characteristics of Hepatocellular Carcinoma With Reactive Ductule-like Components, a Subset of Liver Cancer Currently Classified as Combined Hepatocellular-Cholangiocarcinoma With Stem-Cell Features, Typical Subtype.
Shibahara J; Hayashi A; Misumi K; Sakamoto Y; Arita J; Hasegawa K; Kokudo N; Fukayama M
Am J Surg Pathol; 2016 May; 40(5):608-16. PubMed ID: 26735856
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.
Stroescu C; Herlea V; Dragnea A; Popescu I
J Gastrointestin Liver Dis; 2006 Mar; 15(1):9-14. PubMed ID: 16680226
[TBL] [Abstract][Full Text] [Related]
18. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.
Chen M; Wu L; Tu J; Zhao Z; Fan X; Mao J; Weng Q; Wu X; Huang L; Xu M; Ji J
EBioMedicine; 2018 Sep; 35():142-154. PubMed ID: 30111512
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma.
Sohn BH; Shim JJ; Kim SB; Jang KY; Kim SM; Kim JH; Hwang JE; Jang HJ; Lee HS; Kim SC; Jeong W; Kim SS; Park ES; Heo J; Kim YJ; Kim DG; Leem SH; Kaseb A; Hassan MM; Cha M; Chu IS; Johnson RL; Park YY; Lee JS
Clin Cancer Res; 2016 Mar; 22(5):1256-64. PubMed ID: 26459179
[TBL] [Abstract][Full Text] [Related]
20. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.
Zhao Q; Yu WL; Lu XY; Dong H; Gu YJ; Sheng X; Cong WM; Wu MC
Chin J Cancer; 2016 Aug; 35(1):82. PubMed ID: 27552844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
